D2S Pharma
Turnover is estimated at about €330,000, probably between €200,000 and €630,000. The abbreviated format does not state turnover.
Balance sheet
balance sheet total €582,318 on 30-06-2025in euro
in euro
Position in the sector
72.9%
Higher than 82% of the 84 companies filing abbreviated accounts in pharmaceuticals (NACE 21) in 2025.
5.11
Higher than 85% of the 84 companies filing abbreviated accounts in pharmaceuticals (NACE 21) in 2025.
6.6%
Higher than 74% of the 84 companies filing abbreviated accounts in pharmaceuticals (NACE 21) in 2025.
Net result: middle half · Equity: middle half · Balance sheet total: bottom quarter · Working capital: middle half · Staff: bottom quarter
Staff
€53,819
Staff costs divided by the average number of full-time equivalents.
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 201621 months |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 94,312 | 68,567 | 49,338 | 59,967 | 291,750 | 191,184 | 55,710 | 27,537 | -14,029 | -59,692 | ||
| 78,773 | 59,641 | 46,228 | 53,445 | 225,459 | 159,947 | 53,523 | 24,447 | -15,651 | -69,160 | ||
| 3,313 | 4,936 | 5,436 | 37,578 | 87,027 | 4,611 | 62,967 | 2,200 | 165,700 | 33,163 | ||
| 46,493 | -2,559 | 9,434 | -83,429 | 150,963 | 64,947 | -19,906 | 7,335 | -73,531 | - | ||
| 387,409 | 321,901 | 281,663 | 267,588 | 284,662 | 113,105 | -24,578 | -2,422 | -68,490 | 135 | ||
| 72.9% | 72.0% | 66.2% | 61.0% | 52.5% | 28.8% | 9.5% | 2.6% | 2.3% | 15.5% | ||
| 5.11 | 5.18 | 3.79 | 3.27 | 2.69 | 1.40 | 0.83 | 0.98 | 0.51 | 1.00 | ||
| 2.62 | 2.79 | 1.95 | 1.62 | 1.74 | 0.92 | 0.44 | 0.47 | 0.27 | 0.72 | ||
| 0.37 | 0.39 | 0.51 | 0.64 | 0.90 | 2.47 | 9.54 | 37.71 | 41.95 | 5.43 | ||
| 9.1% | 4.6% | 0.7% | 3.4% | 54.0% | 81.2% | 76.8% | 14.0% | -352.4% | -262.8% | ||
| 6.6% | 3.3% | 0.5% | 2.1% | 28.4% | 23.4% | 7.3% | 0.4% | -8.2% | -40.8% | ||
| 38.25 | 21.94 | 14.31 | 14.13 | - | - | - | - | - | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 201621 months |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||||||
20/58 |
582,318 | 536,409 | 557,033 | 599,904 | 673,445 | 564,207 | 322,557 | 274,321 | 261,706 | 177,361 | |
21/28 |
100,573 | 137,559 | 174,558 | 214,575 | 220,646 | 168,043 | 198,224 | 165,259 | 189,768 | 29,888 | |
21 |
12,547 | 16,871 | 21,195 | 25,519 | 28,000 | 32,303 | 43,777 | 10,695 | 12,913 | 2,863 | |
22/27 |
80,338 | 113,000 | 145,675 | 179,568 | 187,331 | 132,852 | 151,609 | 151,727 | 174,017 | 25,087 | |
23 |
63,355 | 91,423 | 122,748 | 153,085 | 183,059 | 131,440 | 148,014 | 145,948 | 165,981 | 15,974 | |
24 |
2,337 | 4,304 | 2,944 | 4,351 | 4,041 | 949 | 2,902 | 4,854 | 6,880 | 9,113 | |
26 |
14,646 | 17,273 | 19,983 | 22,132 | 231 | 462 | 693 | 924 | 1,156 | - | |
28 |
7,688 | 7,688 | 7,688 | 9,488 | 5,315 | 2,888 | 2,838 | 2,838 | 2,838 | 1,938 | |
29/58 |
481,746 | 398,851 | 382,474 | 385,328 | 452,799 | 396,164 | 124,333 | 109,062 | 71,938 | 147,473 | |
3 |
234,923 | 183,978 | 185,417 | 194,601 | 159,550 | 134,392 | 59,235 | 56,261 | 33,979 | 41,731 | |
30/36 |
234,923 | 183,978 | 185,417 | 194,601 | 159,550 | 134,392 | 59,235 | 56,261 | 33,979 | 41,731 | |
40/41 |
48,666 | 67,002 | 45,875 | 50,147 | 60,263 | 191,372 | 60,059 | 27,763 | 21,767 | 16,057 | |
40 |
48,666 | 66,053 | 42,543 | 44,000 | 55,748 | 178,974 | 60,030 | 27,751 | 20,758 | 10,474 | |
41 |
- | 949 | 3,332 | 6,147 | 4,515 | 12,397 | 29 | 12 | 1,010 | 5,583 | |
54/58 |
188,504 | 142,011 | 144,570 | 135,136 | 218,565 | 67,601 | 2,654 | 22,560 | 15,225 | 88,756 | |
490/1 |
9,652 | 5,860 | 6,613 | 5,445 | 14,422 | 2,799 | 2,384 | 2,479 | 966 | 929 | |
| Balance sheet: equity and liabilities | |||||||||||
10/49 |
582,318 | 536,409 | 557,033 | 599,904 | 673,445 | 564,207 | 322,557 | 274,321 | 261,706 | 177,361 | |
10/15 |
424,697 | 386,223 | 368,518 | 365,944 | 353,632 | 162,596 | 30,607 | 7,087 | 6,093 | 27,565 | |
10/11 |
100,000 | 100,000 | 100,000 | 100,000 | 100,000 | - | 100,000 | 100,000 | 100,000 | 100,000 | |
100 |
- | - | - | - | - | - | 100,000 | 100,000 | 100,000 | 100,000 | |
11 |
- | - | - | - | - | 100,000 | - | - | - | - | |
1100/10 |
- | - | - | - | - | 100,000 | - | - | - | - | |
14 |
324,697 | 286,223 | 268,518 | 265,944 | 253,632 | 62,596 | -69,393 | -92,913 | -93,907 | -72,435 | |
17/49 |
157,621 | 150,186 | 188,515 | 233,960 | 319,814 | 401,611 | 291,949 | 267,235 | 255,613 | 149,796 | |
17 |
60,000 | 69,503 | 83,659 | 112,483 | 146,118 | 116,902 | 141,179 | 153,643 | 113,357 | - | |
170/4 |
60,000 | 69,503 | 83,659 | 112,483 | 146,118 | 116,902 | 141,179 | 153,643 | 113,357 | - | |
42/48 |
94,337 | 76,950 | 100,811 | 117,740 | 168,137 | 283,059 | 148,910 | 111,484 | 140,428 | 147,338 | |
42 |
9,503 | 14,156 | 28,824 | 33,636 | 36,207 | 24,277 | 24,222 | 19,714 | 19,714 | - | |
43 |
3 | - | - | - | - | - | - | - | - | - | |
430/8 |
3 | - | - | - | - | - | - | - | - | - | |
44 |
55,936 | 28,048 | 30,542 | 34,632 | 65,061 | 102,132 | 22,657 | 10,860 | 10,382 | 16,048 | |
440/4 |
55,936 | 28,048 | 30,542 | 34,632 | 65,061 | 102,132 | 22,657 | 10,860 | 10,382 | 16,048 | |
45 |
9,154 | 10,300 | 4,072 | 4,613 | 3,588 | 34,203 | 1,842 | 1,058 | 615 | 925 | |
450/3 |
5,236 | 5,917 | 780 | 1,312 | - | 29,752 | 904 | 110 | - | - | |
454/9 |
3,919 | 4,383 | 3,293 | 3,301 | 3,588 | 4,451 | 937 | 949 | 615 | 925 | |
47/48 |
19,740 | 24,445 | 37,374 | 44,860 | 63,280 | 122,447 | 100,190 | 79,852 | 109,716 | 130,365 | |
492/3 |
3,285 | 3,733 | 4,044 | 3,737 | 5,558 | 1,650 | 1,860 | 2,108 | 1,828 | 2,458 | |
| Income statement | |||||||||||
9900 |
129,195 | 111,075 | 73,834 | 85,449 | 330,648 | 215,278 | 66,632 | 36,434 | -5,662 | -55,161 | |
62 |
26,909 | 32,075 | 23,745 | 24,067 | 28,289 | 16,521 | 9,847 | 7,854 | 6,988 | 1,915 | |
630 |
40,299 | 41,936 | 43,653 | 41,133 | 34,423 | 27,959 | 30,002 | 23,454 | 5,820 | 3,275 | |
631/4 |
- | - | - | - | 4,382 | - | - | - | - | - | |
640/8 |
7,974 | 10,433 | 752 | 1,416 | 6,228 | 7,573 | 1,075 | 1,043 | 1,379 | 2,616 | |
9901 |
54,013 | 26,631 | 5,685 | 18,834 | 257,327 | 163,225 | 25,707 | 4,084 | -19,849 | -62,967 | |
75/76B |
1,667 | 1,552 | 1,821 | 1,337 | 449 | 9 | 1 | 36 | 1 | 12 | |
75 |
1,667 | 1,552 | 1,821 | 1,337 | 449 | 9 | 1 | 36 | 1 | 12 | |
65/66B |
2,466 | 3,125 | 3,448 | 4,245 | 9,123 | 1,494 | 2,188 | 3,126 | 1,624 | 9,480 | |
65 |
2,466 | 3,125 | 3,448 | 4,245 | 9,123 | 1,494 | 2,188 | 3,126 | 1,624 | 9,480 | |
9903 |
53,214 | 25,058 | 4,058 | 15,926 | 248,653 | 161,740 | 23,521 | 993 | -21,472 | -72,435 | |
67/77 |
14,740 | 7,353 | 1,483 | 3,615 | 57,617 | 29,752 | - | - | - | - | |
9904 |
38,474 | 17,705 | 2,575 | 12,312 | 191,036 | 131,988 | 23,521 | 993 | -21,472 | -72,435 | |
9905 |
38,474 | 17,705 | 2,575 | 12,312 | 191,036 | 131,988 | 23,521 | 993 | -21,472 | -72,435 | |
| Appropriation of the result | |||||||||||
9906 |
324,697 | 286,223 | 268,518 | 265,944 | 253,632 | 62,596 | -69,393 | -92,913 | -93,907 | -72,435 | |
14P |
286,223 | 268,518 | 265,944 | 253,632 | - | - | - | - | - | - | |
| Social balance sheet | |||||||||||
9087 |
0.5 | 0.6 | 0.5 | 0.6 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | - | |
Hours worked1013 |
1,200 | 1,428 | 1,022 | 1,188 | 1,504 | 856 | 503 | 375 | 306 | - | |
| Document | |||||||||||
The full notes are in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 20-02-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankThe accounts were filed on 20-02-2026. The deadline was 31-01-2026, 7 months after the close on 30-06-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00042958.
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-06-2025 | abbreviated format | 20-02-2026 | 2026-00042958 | |
| 30-06-2024 | abbreviated format | 07-01-2025 | 2025-00000493 | |
| 30-06-2023 | abbreviated format | 09-02-2024 | 2024-00030283 | |
| 30-06-2022 | abbreviated format | 25-01-2023 | 2023-00006543 | |
| 30-06-2021 | abbreviated format | 28-01-2022 | 2022-03100337 | |
| 30-06-2020 | abbreviated format | 27-01-2021 | 2021-02600274 | |
| 30-06-2019 | abbreviated format | 20-12-2019 | 2019-76800380 | |
| 30-06-2018 | abbreviated format | 23-01-2019 | 2019-02000396 | |
| 30-06-2017 | micro format | 10-01-2018 | 2018-01000385 | |
| 30-06-2016 | abbreviated format | 16-01-2017 | 2017-01300301 |
Subsidies and aid
Flemish government 2023, 1 entry, €126 awarded, €126 paid
Social balance sheet
| Item | 30-06-2025 | 30-06-2024 | 30-06-2023 | 30-06-2022 |
|---|---|---|---|---|
| Employees at the balance-sheet date | 2 | 2 | 2 | 2 |
| part-time | 2 | 2 | 2 | 2 |
| in full-time equivalents | 0.5 | 0.5 | 0.5 | 0.5 |
| 0.5 | 0.6 | 0.5 | 0.6 | |
| On a permanent contract | 2 | 2 | 2 | 2 |
| Joined | - | 1 | 2 | 1 |
| Left | - | 1 | 2 | 1 |
Source: social balance sheet in the 2022 to 2025 annual accounts
Investments
fixed assets acquired| Item | 30-06-2025 | 30-06-2024 | 30-06-2023 | 30-06-2022 |
|---|---|---|---|---|
| Tangible fixed assets | €3,313 | €4,936 | €5,436 | €29,270 |
| Intangible fixed assets | - | - | - | €1,620 |
| Financial fixed assets | - | - | - | €6,688 |
| €40,299 | €41,936 | €43,653 | €41,133 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Insights on D2S Pharma
The operating result for 2025 is 103% higher than in 2024 and the highest since 2021. It is the second rise in a row, after the fall in 2023.
Debt's share of the balance-sheet total falls from 28.0% to 27.1%. Equity and debt are higher.